Elizabeth Silva

Elizabeth Silva

Auto-generated profile, based on publicly available information

Elizabeth Silva

Graduate Division, University of California, San Francisco, San Francisco, CA 94158

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Current Biology
Verified
Journal Article
Closed access
ESElizabeth Silva
Elizabeth Silva
YTYonit Tsatskis
Yonit Tsatskis
LGLaura Gardano
Laura Gardano
NTNic Tapon
Nic Tapon
HMHelen McNeill
Helen McNeill

1 July 2009 in Current Biology
Verified
Journal Article
Closed access
RSRichelle Sopko
Richelle Sopko
ESElizabeth Silva
Elizabeth Silva
LCLesley Clayton
Lesley Clayton
LGLaura Gardano
Laura Gardano
MBMiriam Barrios-Rodiles
Miriam Barrios-Rodiles
HMHelen McNeill
Helen McNeill

1 October 2008 in Cell
Verified
Journal Article
Closed access
LCLeigh Cuttell
Leigh Cuttell
AVAndrew Vaughan
Andrew Vaughan
ESElizabeth Silva
Elizabeth Silva
CEClaire J. Escaron
Claire J. Escaron
MLMark Lavine
Mark Lavine
NFNathalie C. Franc
Nathalie C. Franc

1 August 2004 in Current Biology
Verified
Journal Article
Closed access
ESElizabeth Silva
Elizabeth Silva
STStanley Tiong
Stanley Tiong
MPMichael Pedersen
Michael Pedersen
EHEllen Homola
Ellen Homola
ARAnne Royou
Anne Royou
SCShelagh D Campbell
Shelagh D Campbell

1 April 2016 in Pain
Verified
Journal Article
Open access
NANick A. Andrews
Nick A. Andrews
ALAlban Latrémolière
Alban Latrémolière
ABAllan I. Basbaum
Allan I. Basbaum
JMJeffrey S. Mogil
Jeffrey S. Mogil
FPFrank Porreca
Frank Porreca
GWGarth Whiteside
Garth Whiteside
There is growing concern about lack of scientific rigor and transparent reporting across many preclinical fields of biological research. Poor experimental design and lack of transparent reporting can result in conscious or unconscious experimental bias, producing results that are not replicable. The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration sponsored a consensus meeting of the Preclinical Pain Research Consortium for Investigating Safety and Efficacy (PPRECISE) Working Group. International participants from universities, funding agencies, government agencies, industry, and a patient advocacy organization attended. Reduction of publication bias, increasing the ability of others to faithfully repeat experimental methods, and increased transparency of data reporting were specifically discussed. Parameters deemed essential to increase confidence in the published literature were clear, specific reporting of an a priori hypothesis and definition of primary outcome measure. Power calculations and whether measurement of minimal meaningful effect size to determine these should be a core component of the preclinical research effort provoked considerable discussion, with many but not all agreeing. Greater transparency of reporting should be driven by scientists, journal editors, reviewers, and grant funders. The conduct of high-quality science that is fully reported should not preclude novelty and innovation in preclinical pain research, and indeed, any efforts that curtail such innovation would be misguided. We believe that to achieve the goal of finding effective new treatments for patients with pain, the pain field needs to deal with these challenging issues.

1 October 2007 in Immunity
Verified
Journal Article
Closed access
ESElizabeth Silva
Elizabeth Silva
HAHiu Wan Au-Yeung
Hiu Wan Au-Yeung
EGEmeline Van Goethem
Emeline Van Goethem
JBJemima Burden
Jemima Burden
NFNathalie C. Franc
Nathalie C. Franc